spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  C1-INH 

 HSMN NewsFeed - 25 Jul 2017
HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Mar 2017
New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
Biopharmaceuticals
 HSMN NewsFeed - 16 Mar 2017
Shire Receives European Approval for Label Extension of CINRYZE(R) (C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Jan 2017
European Commission Amends Marketing Authorisation for RUCONEST(R) to Include Self-Administration
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Nov 2016
CHMP Adopts Positive Opinion to Include Self-administration for RUCONEST(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jul 2015
KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Nov 2014
Salix and Pharming Announce the Launch of RUCONEST(R) in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Nov 2013
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jan 2012
CSL Behring Receives FDA Approval of Expanded Label on Berinert(R) for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 22 Mar 2011
Data Presented at AAAAI Annual Meeting Further Support the Safety and Efficacy of FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2011
Shire Files Complete Response to FDA's Not Approvable Letter for FIRAZYR(R) (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jan 2011
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2011
Dyax and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2010
Data from First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2009
Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2009
CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Oct 2008
ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 15 Jul 2008
ViroPharma To Acquire Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Mar 2008
Pharming to receive Negative Opinion on European Marketing Authorization Application for Rhucin(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Mar 2008
CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 26 Jun 2007
Lev Pharmaceuticals, Inc. Announces Completion of Marketing and Sales Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2007
Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2007
Study Finds C1-Inhibitor Concentrate Is Safe and Effective in Treating Skin Swelling in Patients With Hereditary Angioedema
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 14

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 14 additional stories matching:
C1-INH
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!